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Sepsis as life-threatening organ dysfunction caused by microorganisms repre-
sents a dreadful challenge for the immune system. The role of the complement
system as major column of innate immunity has been extensively studied in
various sepsis models, but its translational value remains in the dark. Comple-
ment activation products, such as C3a and C5a, and their corresponding
receptors provide useful diagnostic tools and promising targets to improve
organ function and outcome. However, a monotherapeutic complement inter-
vention irrespective of the current immune function seems insufficient to
reverse the complex sepsis mechanisms. Indeed, sepsis-induced disturbances of
cross talking complement, coagulation, and fibrinolytic cascades lead to sys-
temic ‘thromboinflammation’, ultimately followed by multiple-organ failure.
We propose to reliably monitor the complement function in the patient and to
re-establish the immune balance by patient-tailored combined therapies, such
as complement and Toll-like receptor inhibition. Our working hypothesis aims
at blocking the ‘explosive’ innate immune recognition systems early on before
downstream mediators are released and the inflammatory response becomes
irreversible, a strategy that we name ‘upstream approach’.
Keywords: C3a; C5a; complement activation; sepsis; therapy; Toll-like
receptors
Sepsis comes from the Greek word ‘sepein’ meaning
‘to rot’ reflecting an extreme process of irreversible tis-
sue damage. Others defined sepsis as intoxication of
the blood, emphasizing the dynamic process of sepsis
with exposure to pathogen-associated molecular pat-
terns (PAMPs) generated and released by microorgan-
isms including bacteria, worms, parasites, fungi, and
viruses. In the last three decades, sepsis was defined as
a rather general immune pathophysiologic reaction
with focus on the hemodynamic and pulmonary
response, as well as on temperature and leukocyte
count, clinically known as systemic inflammatory
response syndrome (SIRS) to verifiable bacteria [1].
Only in the last decade, sepsis has been proposed as
life-threatening organ dysfunction caused by a dysreg-
ulated host response to infection [2]. Irrespective of the
definition and modern diagnostic algorithm and inten-
sive care treatment, sepsis remains associated with a
high morbidity and hospital mortality rate reaching
more than 25% in cases of severe sepsis [3]. Thus, sep-
sis represents a major challenge for both clinicians and
scientists.
As for the underlying mechanisms, classical PAMPs
originated from Gram-negative or Gram-positive
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bacteria, such as lipopolysaccharides (LPS) or lipopro-
teins, respectively, were previously in the focus as trig-
gers for sepsis. However, PAMPs from worms,
parasites, fungi, and viruses can also induce sepsis. In
all cases, innate immunity comprising cellular and
fluid-phase defense systems is challenged by microor-
ganisms invading from external (e.g., skin) or internal
(e.g., gut) surfaces via dysfunctional barriers to other-
wise sterile areas of the body [4]. The innate immune
system orchestrates a highly interactive response
against microbes with multiple instruments such as
neutrophils, monocytes and macrophages, dendritic
cells, innate lymphoid cells, and the complement sys-
tem as main players for an effective defense [5]. How-
ever, although designed as protective systems, the
response may become inappropriate and excessively
activated, leading to an unbalanced response that puts
the patient at risk of an overwhelming inflammation
incompatible with life.
The complement system
Complement is part of the host innate defense with a
number of biological effects, many of which contribute
to the inflammatory reaction mainly by activation of
cells like leukocytes and endothelial cells. Previously,
and still correct, complement is regarded as a protec-
tion system against infection, but the recent decades
have shown that complement contributes a number of
other host functions in maintaining the internal tissue
homeostasis [6], including tissue regeneration and ren-
ovation, embryogenesis, neuronal junction regulation
in addition to cross talk with a number of other bio-
logical systems, including the TLRs [7]. However, the
system is a double-edged sword since improper,
enhanced, or uncontrolled activation is disadvanta-
geous and potentially harmful and may be even lethal
for the host in case of septic shock [4].
Complement comprises approximately 50 soluble
and surface bound proteins, acting together in a highly
specific manner and is kept under strict control by reg-
ulatory proteins (Fig. 1). The complement system can
be activated through three pathways (upper part of
Fig. 1), all converging to the cleavage of C3 to gener-
ate C3a and C3b (middle part of Fig. 1). The classical
pathway (CP) is typically activated by antibodies, but
also pentraxins including C-reactive protein (CRP),
serum amyloid P component (SAP), and pentraxin 3
(PTX3) can activate C1. The lectin pathway (LP) is
activated through recognition of carbohydrates by
mannose-binding lectin (MBL), and other collectins as
well as ficolins. Furthermore, LP activation may be
mediated through IgM antibodies, for example, by
those directed against damaged self-antigens. The
alternative pathway (AP) is activated by foreign or
damaged own cells, facilitated by the continuous spon-
taneous hydrolysis of C3. AP also has an important
function in the complement system providing an
amplification loop enhancing C3 activation indepen-
dent of which pathway has been initially activated.
This effect is mainly due to properdin (FP), the only
positive regulator in the complement system, which
stabilizes the C3 convertase. Activation of C3 leads to
formation of a C5 convertase, cleaving C5 into C5a
and C5b.
The anaphylatoxins C3a and C5a bind to the recep-
tors C3aR, C5aR1, and C5aR2, leading to down-
stream production of inflammatory mediators (lower
left part of Fig. 1). C5b initiates the formation of the
terminal C5b-9 complement complex (TCC), which
forms the membrane attack complex if inserted into a
membrane (bottom part of Fig. 1). This may lead to
lysis of bacteria and cells or in sublytic doses to activa-
tion of cells. The cleavage and inactivation of C3b
generate iC3b, which binds to complement receptors
CR3 (CD11b/CD18) and CR4 (CD11c/CD18), facili-
tating phagocytosis, oxidative burst, and downstream
inflammation (right part of Fig. 1). The complement
system is tightly regulated by soluble inhibitors
(marked in yellow in Fig. 1), including C1-inhibitor
(C1-INH), factor H (FH), factor I (FI), C4b-binding
protein (C4BP), anaphylatoxin inhibitor (AI), vit-
ronectin (Vn), and clusterin (Cl), keeping the continu-
ous low-grade activation in the fluid phase in check.
Host cell membranes are equipped with a number of
inhibitors to protect them against attack by comple-
ment (right part of Fig. 1), including membrane cofac-
tor protein (MCP;CD46), complement receptor 1
(CR1;CD35), decay accelerating factor (DAF;CD55),
controlling C4 and C3 activation, and CD59 protect-
ing against final assembly of the C5b-9 complex.
Investigation of complement
activation mechanisms in ex vivo
sepsis ‘surrogate’ models
Sepsis is a clinical condition, requiring the whole body
of the host to interact with the microbes, which are
growing in the circulation and infiltrating organs
through a disturbed vascular endothelium. Since
ex vivo models do not fulfill the criteria for the term
sepsis as a multi-organ response, they are not termed
sepsis models, but rather models for bacteria-induced
inflammation. These can be highly reductionistic,
studying the interaction of the microbe with specific
cell population in purified systems. Such models are
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valuable to study ligand–receptor interactions and the
subsequent intracellular signaling pathways. Targeting
specific molecules in these signal pathways are useful
to test potential therapeutic approaches both by block-
ing (antagonists) and by enhancing (agonists) the
actual signaling pathway. Various microbe–cell interac-
tion models both with single cells and more complex
cell cultures have been reviewed [8].
We have developed a more holistic ex vivo model
based on freshly drawn human whole blood, which is
anticoagulated with lepirudin, which is a highly speci-
fic thrombin inhibitor [9]. Traditional anticoagulants
like EDTA and citrate bind calcium, thus precluding
them for being used when that aim is to explore the
interaction between the various biological systems of
which most are dependent on free calcium. Heparin
interferes not only with many steps of the coagulation
cascade, but also with the complement system and
should be used with great caution. Our lepirudin-based
model inhibits only thrombin, the second last step of
coagulation. Thus, despite the limitation of the model
that the role of thrombin cannot be evaluated, it is as
close to a physiological system as is possible to come
using whole blood.
The role of complement in the inflammatory reac-
tion in human whole blood has been extensively stud-
ied in this model using both Gram-negative and
Gram-positive bacteria. Various complement inhibitors
as well as whole blood form otherwise healthy C5-defi-
cient individuals were used to study the effect of com-
plement activation on the inflammatory reaction
including leukocyte and platelet activation, cytokine
release, oxidative burst, receptor expression, and
arachidonic acid production [10]. Complement activa-
tion, in particular of C5 with release of C5a and subse-
quent binding to its receptor C5aR1, was responsible
for a number of the secondary inflammatory mediators,
in particular those related to neutrophil activation like
Fig. 1. Overview over the complement system. The content of the figure is described in detail in the section entitled ‘The complement
system’.
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oxidative bust and granula release, receptor expression,
and IL-8 release. The effect of the rest of the cytokine
panel was less complement driven. This led us to search
for the role of another important upstream recognition
system of innate immunity, the Toll-like receptor (TLR)
system. CD14 is an important coreceptor for several
TLRs, including TLR4 and TLR2, both of which are
important sensors of PAMPs [11]. Thus, we used the
same whole blood model and inhibited the same panel
of inflammatory markers induced by the same bacteria
using an anti-CD14 antibody [10]. We then found a dif-
ferential pattern with the most extensive effects on the
typical pro-inflammatory cytokines including IL-6,
TNF, and IL-1b. Most importantly, we found that a
combined inhibition of C5 and CD14 virtually abol-
ished the whole inflammatory reaction.
Based on these data, we developed the hypothesis
that dual blockade of both complement (e.g., C3, C5,
or C5aR1) and the TLR molecule CD14, binding LPS
captured by LPS-binding protein (LBP) in plasma
bringing it to TLR4, was a potent way of attenuation
the overwhelming inflammatory response induced by
Gram-positive as well as Gram-negative bacteria [12].
In a number of studies, we showed that this combined
inhibition was a promising strategy for future therapy,
reviewed in [13,14], paving the way for animal experi-
ments described below. In order to investigate how
potent this combined regimen was, we performed a
microarray study of human whole blood exposed to
Escherichia coli (E. coli) in the absence or presence of
the combined treatment approach [15]. In this model,
2335 genes significantly responded to E. coli. by on
average 80%. Combined inhibition significantly
reversed 70% of these transcriptional changes by an
average of 80%, underscoring an extensive and broad-
acting effect of this inhibition in a bacterial model.
Determination of the effects of
complement modulation during sepsis
in animal models
Rodents
Multiple models exist for the scientist to simulate sys-
temic inflammation following an infectious insult.
However, in real world, the clinician usually faces a
more complex immune pathophysiology induced by
other situations than just an artificial LPS intoxication
or inoculation of a single specific bacterium. To simu-
late sepsis in a clinically more relevant manner, cecal
ligation and puncture (CLP) in rodents [16] or cecum
incision in pigs [17] (see below) seems rather reliable
and considered currently as a golden standard for
translational meaningful polymicrobial sepsis research
[18]. In rodent CLP sepsis, acute-phase protein,
transferrin, and C3 production by the liver was
increased as early as 16 h after CLP induction as deter-
mined in ex vivo hepatic perfusion analyses [19] and
remained more than twofold even 96 h after induction
of sepsis [20]. Systemic complement activation with gen-
eration of the complement activation products C3a and
C5a was shown in many studies in rodent sepsis [21].
However, blockade of C3 or C4 by genetic deficiency
resulted in impaired endotoxin clearance and worsened
the septic course and outcome in an LPS intoxication
model [22]. Furthermore, C3 knockout mice were also
very susceptible to CLP-induced sepsis [23]. In contrast,
C5 inhibition by antibodies and C6 deficiency in rats
significantly improved animal survival [24]. Another
study reported some protection in C3-deficient mice
undergoing CLP sepsis but no survival advantage of
C5-deficient mice [25]. In line, a recent CLP sepsis study
revealed that upregulation of microRNA-574 which
gen-targets and downregulates C3, attenuated septic
lung injury and reduced sepsis-induced stress of the
endoplasmic reticulum [26].
There are several studies indicating improved cellular
function, organ performance, and survival of CLP
sepsis mice by several inhibition strategies of the inter-
action between C5a and the corresponding receptor
C5aR1 or C5aR2 [27–30]. Of note, in severe sepsis, syn-
chronic inhibition of both, C5aR1 and C5aR2, revealed
a survival benefit over single blockade strategy [28].
For blockade of the C3aR in CLP sepsis, little is
known. One study showed in murine endotoxin shock
an enhanced mortality rate when C3aR was absent
[31]. Another study in LPS-induced shock with sys-
temic inflammation demonstrated an early enhanced
lethality rate of C3aR-deficient mice, but after a 72-h
observation period, no changes could be detected
between the wild-type and C3aR-deficient littermates
[32]. In experimental meningococcal sepsis, a differen-
tial role for the C3aR and the C5a receptors has
recently been reported: whereas C5aR1 and C5aR2
aggravated the disease immune pathology, C3aR was
rather protective [33]. Thus, C3a seems to reveal some
protective effects, possibly by activating the hypothala-
mus–pituitary–adrenal axis and by inhibition of neu-
ronal cell death [32].
In striking contrast, C5a seems to induce all classical
signs of inflammation and has been proposed to be
harmful when excessively produced [34]. Mechanisti-
cally, C5a generation during sepsis as a most potent
chemotactic factor for neutrophils can switch the
endothelium from antiadhesive to pro-adhesive for
inflammatory cells by upregulation of various selectins
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[35]. C5a can also result in the disruption of the
endothelial barrier by neutrophil protease-mediated
degradation of VE cadherin [36]. Furthermore, C5a
can transform leukocyte surfaces to a pro-coagulatory
platform [37,38]. Upon recruitment, C5a can activate
leukocytes to mount an oxidative burst, which is not
only microbicidal but also host-attacking. However,
during advanced sepsis and upon exposure to excessive
C5a, neutrophils become ‘paralysed’ and may not
response to chemotactic signals. Their NADPH oxi-
dase activity will be lost by translocation defects of
key activation enzymes (e.g., p47phox) and lead to an
impaired phagocytotic activity and bacterial clearing
[27,39]. Therefore, bacteria can further expand, drive
sepsis progression, and worsen clinical outcome [27].
Sepsis in the clinical setting is currently defined as
(multiple) organ dysfunction [2]. In this context, C5a
has detrimental effects to several organs as previously
shown [40]. During rodent CLP sepsis, pulmonary gas
exchange was compromised, liver enzyme levels ele-
vated, urine output and glomerular filtration rate
reduced with ultrastructural changes of the glomerular
filter, and lactic acidosis present. All these pathological
changes could be prevented by blockade of systemic
C5a [17]. Furthermore, sepsis-induced coagulopathy
could be alleviated by anti-C5a therapeutic strategies
[41]. In addition, applying a C5a-neutralizing mirror
image (L-) aptamer (C5a-Spiegelmer; an RNA frag-
ment binding and blocking C5), mice with CLP-in-
duced sepsis exhibited less signs of gut barrier
dysfunction and multiple-organ failure even when
applied 6 h after the infectious insult [29]. With the
same C5a-neutralizing strategy, pneumococcal pul-
monary sepsis in mice could also be improved [42].
Using anti-C5a antibodies, the delayed application of
the immune modulation could last up to 12 h after
CLP and still resulted in an improved outcome [43].
Remarkably, C5a seems also to be involved in devel-
opment of septic cardiomyopathy with dysfunction of
cardiomyocytes, which could be almost normalized by
neutralizing C5a [44].
Taken together, C5a inhibitory strategies in small
animals with sepsis simulation seem promising on a
cellular, immune, and multiple-organ levels and, there-
fore, have been translated to higher species so as to
assess its potential for clinical application (Fig. 2).
Large animals
In contrast to rodents, very few studies have been per-
formed using complement inhibitors in large animal
sepsis studies. Some reports on C1-inhibition have
been published, but since the C1-inhibitor is not a
specific complement inhibitor, but inhibits all plasma
cascade systems, we have not included these here. It is
well known that the pathophysiology caused by C1-in-
hibitor deficiency is due to bradykinin formation from
the contact activation system [45].
We established a pig model of intravenous E. coli
sepsis with the aim of investigating a broad panel of
physiological, inflammatory, and hemostatic parame-
ters [46]. At that time, we already had established the
Fig. 2. Possible complement modulatory
strategies for excessive complement
activation and the subsequent signs of
cellular and organ dysfunction during
sepsis. Blue arrows: activation/stimulation;
red arrows: inhibition.
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complement and CD14 dual blockade. Thus, we inves-
tigated the efficacy of blocking C5 alone or in combi-
nation with an anti-CD14 antibody. To block C5, we
used Ornithodoros moubata complement inhibitor
(OmCI), also known as coversin. Anti-CD14 (mAb
MIL-2) was modified by making it a chimeric IgG2/4,
which did not show diverse effects due to Fc-mediated
effector functions, but completely neutralized CD14
[47]. Of interest, C5 blockade not only completely
inhibited complement terminal activation, but also
abolished leukotriene B4 formation, and significantly
reduced granulocyte tissue factor expression. Forma-
tion of thrombin–antithrombin complexes and forma-
tion of TNF and IL-6 were efficiently inhibited by
OmCI alone, supporting a cross talk with coagulation,
that is, ‘thromboinflammation’. When anti-CD14 was
added together with OmCI, these mediators were vir-
tually abolished, indicating the potency of the dual
inhibition. Additionally, the combined therapy attenu-
ated the formation of plasminogen activator inhibitor-
1 (P < 0.05), IL-1b, and IL-8, increased the formation
of IL-10, and abolished the expression of wCD11R3
(CD11b) and the fall in the neutrophil cell count.
Finally, the combined treatment also improved the
cardiopulmonary functions by delaying the increases in
the heart rate and mean pulmonary artery pressure.
We then investigated the effects of the combined inhi-
bition on the local inflammatory response in liver, kid-
ney, lung, and spleen from these animals [48]. All
cytokines were reduced in all organs and the therapy
attenuated upregulation of C5aR in the heart and
lungs, which could explain the beneficial effects on the
cardiopulmonary functions.
Similar to the model described above, we tested the
dual inhibition in Neisseria meningitis sepsis by
intravenous infusion of escalating doses of bacteria
[49]. The dual inhibition markedly attenuated the
cytokine storm, which developed rapidly in the
untreated animals, similar to the human meningococ-
cal sepsis, by significantly inhibiting interferon-
gamma, TNF, IL-8, IL-10, IL-12p40, and granulocyte
CD11b (CR3) expression. Thus, inhibition of C5 and
CD14 may be beneficial in treatment of Gram-nega-
tive sepsis in general.
In clinical medicine, polymicrobial sepsis is com-
mon, frequently presented with several Gram-negative
and Gram-positive bacteria, typically seen in sepsis
originated from peritonitis. As described above, we
have tested mice with the CLP model of sepsis and
found that dual inhibition both increased survival
and decreased inflammation as compared to single
inhibition. Though, this mouse model is regarded as
a highly relevant model for sepsis, ‘mice are not man’
[50]. Thus, in order to move closer to the clinic, we
developed a peritonitis model in pigs by making a
2 cm cut in cecum [17]. Peritonitis developed rapidly
and led to polymicrobial severe sepsis, septic shock,
and many deaths throughout the 8-h observation per-
iod. Treatment was performed with the same inhibi-
tors of C5 and CD14 as described for the Gram-
negative bacteria studies. Dual inhibition improved
cardiopulmonary function, reduced the cytokine
storm, and, most importantly, significantly improved
survival. Of the 12 animals in each group, nine sur-
vived in the treatment group and four in the non-
treated group.
Even closer to humans are nonhuman primates. In a
primate study of E. coli sepsis, an anti-C5a antibody
was shown to attenuate the septic shock and reduced
leukocyte-mediated lung edema [51]. In a well-estab-
lished baboon model of intravenously induced E. coli
sepsis, inhibition of C3 by the small molecule comp-
statin, the authors investigated the effect of comple-
ment inhibition on hemostasis [52]. C3 inhibition
reduced leukopenia and thrombocytopenia and low-
ered the accumulation of macrophages and platelets in
organs. It decreased the coagulopathic response by
downregulating tissue factor and PAI-1, diminished
global blood coagulation markers like fibrinogen, fib-
rin degradation products, and APTT, and preserved
the endothelial anticoagulant properties. Furthermore,
compstatin effectively reduced tissue damage as evalu-
ated by histopathology.
We followed this track by investigating the effect
of C5 inhibition in the same baboon E. coli sepsis
model [53]. C5 cleavage was blocked by RA101295, a
2-kDa macrocyclic peptide. RA101295 reduced the
E. coli-induced ‘oxidative burst’, as well as leukocyte
activation, without affecting phagocytosis. RA101295
treatment reduced the LPS content in plasma, imply-
ing reduced complement-mediated bacteriolysis,
whereas treated animals showed slightly improved
bacterial clearance during the bacteremic stage com-
pared with controls. Treatment also improved con-
sumptive coagulopathy, preserved endothelial
anticoagulant and vascular barrier functions, and
reduced cytokines. Overall, RA101295 treatment was
associated with significant cardiovascular improve-
ment and organ protection and, most importantly,
markedly reduced mortality as four of five animals
survived in this 100% lethal model. We therefore con-
clude that inhibition of C5 cleavage during the bac-
teremic stage of sepsis could be an important
therapeutic approach to prevent sepsis-induced
inflammation, consumptive coagulopathy, and subse-
quent organ failure and death.
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Translational approaches of
complement monitoring and
modulation in clinical sepsis
Various clinical studies have demonstrated in patients
with severe sepsis a robust complement activation with
enhanced concentrations of complement factor B [54]
and generation of C3a, C4a, and C5a. The anaphyla-
toxin production in particular seems to be associated
with a bad outcome [55–62]. In patients suffering from
necrotizing soft tissue infections with or without septic
shock, complement activation was evident and high
levels of the C4c/C4 ratio, C3bc, and the C3bc/C3
ratio were associated with an enhanced long-term mor-
tality [63]. Patients with severe tissue trauma also
exhibited enhanced C3a and C5a plasma levels espe-
cially when they developed septic complications
[64,65]. The systemic concentrations of C3 and C5
dropped whereas C3a and C5a significantly increased
early during sepsis and normalized when successfully
treated [66].
C3a was the best variable to differentiate between
sterile SIRS and sepsis in humans with a maximal sen-
sitivity of 86% and a specificity of 80% [67]. For C5a,
the discriminatory power to reliably diagnose sepsis
versus systemic inflammation or healthy conditions is
problematic. Likely, most of the excessively generated
C5a is rapidly bound to the almost ubiquitous
expressed C5a receptors (C5aR). In contrast, expres-
sion of the C5aR on neutrophils seems a rather sensi-
tive tool. Injection of E.coli LPS (2 ngkg1 body
weight) into healthy volunteers resulted among others
in a decrease of the C5aR associated with functional
cellular impairment [68]. First reports in patients with
sepsis indicated that a decreased C5a-C5aR interaction
on neutrophils occurred during sepsis development
[69]. Meanwhile, determination of C5aR1 or C5aR2
on neutrophils by flow cytometric methods seems a
reliable tool for various intensive care patients to early
diagnose sepsis with a satisfying sensitivity and speci-
ficity [62,70–72]. Human neutrophils, central in the
first line of cellular defense, exhibit only minor func-
tional changes when activated by C3a, resulting, for
example, in mounting of an oxidative burst [73]. Fur-
thermore, LPS exposure is capable to upregulate C3aR
on neutrophils and thereby inducing neutrophil extra-
cellular trap (NET) formation [74].
In striking contrast, presence of C5a results in multi-
ple changes of human neutrophils [75] including depo-
larization of the membrane potential [76] shape
changes [77], phagocytosis, and generation of reactive
oxygen radicals (ROS). Furthermore, C5a seems to
function as a switch of the pH resulting in intracellular
alkalinization followed by enhanced glycolytic flux and
production of a lactic acidosis in the extracellular
microenvironment of the cells [78]. In accordance, neu-
trophils isolated from patients with severe sepsis
revealed an elevated intracellular pH [78]. Based on all
the reported small and large animal studies, where C5a
inhibitory strategies revealed some cellular and organ
protection and improved outcome it was rational to
transfer these results from the scientific platform into
the clinics. Thus, an extracorporeal immunoabsorption
device to clear LPS, IL-6, and C5a was tested and
could successfully reduce systemic C5a levels from ca.
300 to ca. 80 ngmL1. Moreover, impairment of
monocytic function was reversed and some improve-
ment of the organ functions achieved [79]. Further-
more, a sepsis study ‘Studying Complement Inhibition
in Early, Newly Developing Septic Organ Dysfunction
(SCIENS)’ has been performed in patients with
advanced sepsis using a humanized monoclonal anti-
body against human C5a (NCT02246595). Although
the recruitment phase has been finished, the results are
pending.
Taken together, C5aR status on neutrophils, rapidly
assessed by flow cytometric methods, may be useful to
monitor the risk to develop infectious complications in
ICU and sepsis patients [62,70,72]. However, the bene-
fit of C5a inhibitory strategies in human sepsis in clini-




Concerning sepsis-induced multiple-organ dysfunction
syndrome (MODS), barrier dysfunction seems a major
underlying immune pathophysiological driver. Comple-
ment activation products may cause or at least help
impair endothelial organ barriers, clinically manifested
as capillary leakage syndrome [80,81]. Thus, one
important future goal is to modulate the complement
in order to treat capillary leakage. Immunoadsorption,
hemofiltration, or hemodialysis approaches to remove
complement activation products [82–84] may reduce
systemic inflammation and thereby result in an
improved outcome. Further clinical trials need to
address and assess this potential.
Indirect modulation of systemic complement activa-
tion may also improve cellular and organ performance
and outcome. For example, sIL-1R antagonist attenu-
ated generation of C3a and thrombin–antithrombin
complexes, as well as key fibrinolysis markers, during
sepsis in humans [85].
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Attention should be paid to potential cardiotoxic
effects of complement activation products. It has been
shown that C3a or C5a generated during sepsis in
humans can alter cardiomyocyte function [86,87] and
may be directly involved in causing hemodynamic dis-
turbances and a fatal outcome [88]. Here, further
research on the proposed cardiocomplement cross talk
is required.
Both basic research and clinical research are neces-
sary to better define the role of complement during
fungus-induced sepsis. Although considered in general
harmful during sepsis [34], C5a may also control early
fungal invasion by promoting recognition and clear-
ance of fungi by neutrophils [89]. However, the com-
plement defense is also time-dependent and, in later
periods of sepsis, C5a may play a different role [89].
Thus, irrespective of the complement modulatory strat-
egy used, it seems mandatory to monitor actual com-
plement function in accordance to the principle
‘measure what your target’. Here, bedside tests are
needed to reliably assess actual complement activity or
depletion. Rebalancing the activity of complement
could be useful as a potential immunomodulatory
therapy.
Summary—specific therapeutic approach in
sepsis is to ‘look upstream’
Sepsis is a complex spectrum of clinical entities, a big
challenge when it comes to clinical trials. Except
antibiotics and supportive therapy, there is no specific
treatment for sepsis. Due to the diversity of the dis-
ease, it is unsurprising that all clinical using specific
inhibition of single downstream inflammatory media-
tors such as TNF, IL-1b, or IL-6 trials has failed [14].
Similarly, also single inhibition of TLR4 (Eritoran)
[90] or activated protein C (Xigris) [91] has failed.
Stratification of patients is also a big problem: It is
vital to determine at which stage of the process leading
from infection to septic shock treatment needs to be
started. Knowing the cause of sepsis is crucial as well
to find an appropriate therapy. Thus, all of these fac-
tors should be carefully weighed when designing a
treatment regimen for sepsis.
Our hypothesis is to block the complement system
in sepsis, but, based on the data presented above, we
frankly admit that this is not sufficient. Complement is
important, but the other recognition systems are
important as well, and a combination of inhibition of
other upstream molecules like CD14 in the TLR sys-
tem seems to be a promising approach [14,92]. During
development of sepsis, the innate immune system,
including the plasma cascades, gradually reaches a
point where it is impossible to save the life of the
patient—the so-called ‘the point of no return’. These
cascades represent undetonated bombs, which may
detonate in sepsis. A prerequisite for our hypothesis is
that inhibition should be given long before ‘the point
of no return’ is reached. To avoid an explosive sepsis,
we need to treat the patients at high risk, ideally
before they develop sepsis. High-risk patients include
those undergoing abdominal surgery with postopera-
tive peritonitis, or patients with open heart surgery or
after major trauma. Treatment should be initiated
before development of SIRS and eventually sepsis has
occurred, so that the cytokine storm may be pre-
vented.
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